Competition Medicine Pharmaceutical manufacturing 
European Pharmaceutical Review
FEBRUARY 13, 2025
Based on the new cost estimates, pharmaceutical manufacturers in Finland alone will be required to fund 280816 million of these expenses, The directive , enforced on 1 January 2025, imposes an extended manufacturer responsibility on the removal of micro-pollutants from wastewaters.
European Pharmaceutical Review
SEPTEMBER 28, 2023
According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), more than 600 essential medicines are at risk if a proposed restriction on the use of fluorinated substances, per- and polyfluoroalkyl substances (PFAS) across pharmaceutical manufacturing in the EEA, is implemented.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JULY 15, 2022
The pharmaceutical sector is not typically seen as a highly polluting, ‘heavy industry’ but it is far from green. In its 2021 report Delivering a ‘Net Zero’ National Health Service , the UK’s NHS attributes as much as a quarter of its carbon footprint to medicines. There is also a reputational imperative to act on carbon emissions.
pharmaphorum
JANUARY 24, 2023
Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. Since 2010, the UK has fallen from 4th to 98th place in overall trade balance in pharmaceuticals, due to fierce global competition, according to the MMIP.
European Pharmaceutical Review
APRIL 11, 2024
Globally, the pharmaceutical sector emitted around 52 megatonnes of CO 2 in 2015, the most recent period for which detailed numbers are available. megatonnes in the same year, and the increased demand and complexity of medicines since then will only have swollen this figure. 1 That’s more than the automotive sector, which released 46.4
European Pharmaceutical Review
AUGUST 29, 2024
A major new £400 million public-private collaboration has launched in the UK, aimed at enhancing the life sciences sector’s economic growth and the competitiveness over the next five years. The innovative programme is set to strengthen clinical trials and improve medicine manufacturing in the UK.
Impetus Digital
AUGUST 2, 2024
Personalized Medicine AI can help develop precision medicine by analyzing patient data , including demographic, clinical, and genetic information, as well as information about their metabolism and microbes, environmental exposures, and lifestyle factors, to predict how different patients will respond to various therapies.
Expert insights. Personalized for you.
59 
Let's personalize your content